Literature DB >> 24900152

The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma.

Sinae Lee1, Taegyu Park1, Soyeon Park1, Kisoo Pahk2, Seunghong Rhee2, Jaehyuk Cho2, Eugene Jeong2, Sungeun Kim1, Jae Gol Choe2.   

Abstract

Thyroid incidentalomas are common findings during imaging studies including (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for cancer evaluation. Although the overall incidence of incidental thyroid uptake detected on PET imaging is low, clinical attention should be warranted owing to the high incidence of harboring primary thyroid malignancy. We retrospectively reviewed 2,368 dual-time-point (18)F-FDG PET/CT cases that were undertaken for cancer evaluation from November 2007 to February 2009, to determine the clinical impact of dual-time-point imaging in the differential diagnosis of thyroid incidentalomas. Focal thyroid uptake was identified in 64 PET cases and final diagnosis was clarified with cytology/histology in a total of 27 patients with (18)F-FDG-avid incidental thyroid lesion. The maximum standardized uptake value (SUVmax) of the initial image (SUV1) and SUVmax of the delayed image (SUV2) were determined, and the retention index (RI) was calculated by dividing the difference between SUV2 and SUV1 by SUV1 (i.e., RI = [SUV2 - SUV1]/SUV1 × 100). These indices were compared between patient groups that were proven to have pathologically benign or malignant thyroid lesions. There was no statistically significant difference in SUV1 between benign and malignant lesions. SUV2 and RI of the malignant lesions were significantly higher than the benign lesions. The areas under the ROC curves showed that SUV2 and RI have the ability to discriminate between benign and malignant thyroid lesions. The predictability of dual-time-point PET parameters for thyroid malignancy was assessed by ROC curve analyses. When SUV2 of 3.9 was used as cut-off threshold, malignancy on the pathology could be predicted with a sensitivity of 87.5 % and specificity of 75 %. A thyroid lesion that shows RI greater than 12.5 % could be expected to be malignant (sensitivity 88.9 %, specificity 66.3 %). All malignant lesions showed an increase in SUVmax on the delayed images compared with the initial images. But in the group of benign lesions, 37.5 % (6/16) showed a decrease or no change in SUVmax. Dual-time-point (18)F-FDG PET/CT, obtaining additional images 2 h after injection, seems to be a complementary method for the differentiation between malignancy and benignity of incidental thyroid lesions.

Entities:  

Keywords:  18F-FDG PET/CT; Delay scan; Dual-phase PET; Dual-time-point imaging; Retention index; SUVmax; Thyroid incidentaloma

Year:  2013        PMID: 24900152      PMCID: PMC4028480          DOI: 10.1007/s13139-013-0247-z

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  35 in total

1.  Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.

Authors:  Takayoshi Shinya; Soichiro Fujii; Shoji Asakura; Toshitaka Taniguchi; Kotaro Yoshio; Aierken Alafate; Shuhei Sato; Tadashi Yoshino; Susumu Kanazawa
Journal:  Ann Nucl Med       Date:  2012-06-13       Impact factor: 2.668

Review 2.  18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer.

Authors:  M P Stokkel; K G Moons; F W ten Broek; P P van Rijk; G J Hordijk
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

3.  A PET study of 18FDG uptake in soft tissue masses.

Authors:  M A Lodge; J D Lucas; P K Marsden; B F Cronin; M J O'Doherty; M A Smith
Journal:  Eur J Nucl Med       Date:  1999-01

4.  Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm.

Authors:  Inga-Lena Nilsson; Fabian Arnberg; Jan Zedenius; Anders Sundin
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

5.  Chronic thyroiditis: diffuse uptake of FDG at PET.

Authors:  S Yasuda; A Shohtsu; M Ide; S Takagi; W Takahashi; Y Suzuki; M Horiuchi
Journal:  Radiology       Date:  1998-06       Impact factor: 11.105

6.  Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.

Authors:  Jeong Won Lee; Seok-Ki Kim; Sang Mi Lee; Seung Hwan Moon; Tae-Sung Kim
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

7.  Value of positron emission tomography for lung cancer staging.

Authors:  J M Albes; B M Dohmen; U Schott; E Schülen; M Wehrmann; G Ziemer
Journal:  Eur J Surg Oncol       Date:  2002-02       Impact factor: 4.424

8.  Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.

Authors:  Danny L Costantini; Reza Vali; Jeffery Chan; Susan McQuattie; Martin Charron
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.

Authors:  Alexander Matthies; Marc Hickeson; Andrew Cuchiara; Abass Alavi
Journal:  J Nucl Med       Date:  2002-07       Impact factor: 10.057

10.  High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.

Authors:  S Yamada; K Kubota; R Kubota; T Ido; N Tamahashi
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  9 in total

1.  Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.

Authors:  Byung Hyun Byun; Sung Hoon Kim; Sang Moo Lim; Ilhan Lim; Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jae-Soo Koh; Soo Kyo Chung
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

2.  Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.

Authors:  Taegyu Park; Sinae Lee; Soyeon Park; Eunsub Lee; Kisoo Pahk; Seunghong Rhee; Jaehyuk Cho; Chulhan Kim; Jae Seon Eo; Jae Gol Choe; Sungeun Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-28

3.  Characteristics of malignant thyroid lesions on [18F] fluorodeoxyglucose (FDG)-Positron emission tomography (PET)/Computed tomography (CT).

Authors:  Hatem Nasr; Hussein Farghaly; Abdullah Alqarni; Seham Al-Salem; Mohamed Sayed
Journal:  Eur J Radiol Open       Date:  2021-08-19

4.  The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.

Authors:  Martin Barrio; Johannes Czernin; Michael W Yeh; Miguel F Palma Diaz; Pawan Gupta; Martin Allen-Auerbach; Christiaan Schiepers; Ken Herrmann
Journal:  Nucl Med Commun       Date:  2016-12       Impact factor: 1.690

5.  Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma.

Authors:  Huazheng Shi; Zuguo Yuan; Zheng Yuan; Chunshan Yang; Jian Zhang; Yi Shou; Wenrui Zhang; Zhaofu Ping; Xin Gao; Shiyuan Liu
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

6.  [18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results.

Authors:  M Sollini; L Cozzi; G Pepe; L Antunovic; A Lania; L Di Tommaso; P Magnoni; P A Erba; M Kirienko
Journal:  Eur J Hybrid Imaging       Date:  2017-10-12

7.  Diagnostic Accuracy of Dual-Time-Point Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Verification Local Recurrence in Pancreatic Cancer Patients.

Authors:  Esraa El-Kholy; Lobna Khaled
Journal:  Indian J Nucl Med       Date:  2019 Oct-Dec

8.  The dilemma of 18F-FDG PET/CT thyroid incidentaloma: what we should expect from FNA. A systematic review and meta-analysis.

Authors:  Lorenzo Scappaticcio; Arnoldo Piccardo; Giorgio Treglia; David N Poller; Pierpaolo Trimboli
Journal:  Endocrine       Date:  2021-03-24       Impact factor: 3.633

9.  Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.

Authors:  Ji-hoon Jung; Choon-Young Kim; Seung Hyun Son; Do-Hoon Kim; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.